Interferons
Type | Receptor | Secreting cell / action |
IFN type I IFN-α (1, 2, 4, 5, 6, 7, 8, 10, a3, 14, 16, 17, 21), IFN-β (1, 3), IFN-κ, IFN-δ, IFN-ε, IFN-τ, IFN-ω (with pseudogenes), IFN-ζ (limitin) |
IFN-α receptor (IFNAR) IFNAR1 and IFNAR2 chains |
plasmacytoid dendritic cells (pDCs) are the most potent producers of type I IFNs, but virtually all cells are capable of production of type I IFNs – lymphocytes (NK cells, B cells, T cells), macrophages, fibroblasts, endothelial cells, osteoblasts IFN-β is expressed primarily in nonimmune cells, and and IFN-α primarily in leukocytes |
IFN type II single isotype IFN-γ |
IFN-γ receptor (IFNGR) IFNGR1 and IFNGR2 |
activated T cells, Th1 cells, and natural killer cells. potentiates the effects of the type I IFNs, stimulates macrophages to kill engulfed bacteria, regulates Th2 response, regulation of immune response (IFN-γ production can lead to autoimmune disorders) |
IFN type III types IFN-λ1(IL29), IFN-λ2 (IL28A), IFN-λ3 (IL28B) (originally called macrophage-activating factor) |
IL10R2 (CRF2-4) plus IFNLR1 (CRF2-12) | IFN-λs induced by both type I and type III IFNs (belong to IFN-stimulated genes (ISGs)) induced after stimulation by viruses and display antiviral activity IFN-λs are produced by plasmacytoid dendritic cells to a greater extent than by myeloid dendritic cells |
specific interferons | actions |
|
IFN-β1a (Avonex, Rebif) | employed in treatment of multiple sclerosis (MS, DS) | |
IFN-β1b (Betaseron) | employed in treatment of multiple sclerosis (MS, DS) | |
0 Comments:
Post a Comment
<< Home